The approval of poly-ADP ribose polymerase (PARP) inhibitors for the treatment of BRCA1/2-mutated advanced ovarian cancers and more recently for BRCA1/2-mutated breast cancers illustrates the potential of SL-based therapeutics (Bryant et al. 2005; Farmer et al. 2005; Kim et al. 2015). The gene discussed is BRCA1; the disease is ovarian carcinoma.